FTC finalizes its rule on consumer reviews and testimonials

The Federal Trade Commission finalized a rule on August 14, 2024, that bans fake and deceptive consumer reviews, undisclosed insider reviews, review hijacking, and company-run websites that pretend to be independent ^[1]. The rule, codified at 16 CFR Part 465, took effect October 21, 2024 ^[1]. It applies broadly to advertising and marketing across the internet, including the crowded field of GLP-1 content built around semaglutide products like Ozempic, Wegovy, and Rybelsus, and tirzepatide products like Mounjaro and Zepbound ^[1].

The FTC's notice lists several specific practices the rule targets. Companies can no longer write, buy, or use fake reviews or testimonials, including ones generated to look like they came from real customers ^[1]. Businesses cannot post reviews from company insiders, such as employees or their relatives, without clearly disclosing the connection ^[1]. The rule also bars "review hijacking," where a company takes reviews written for one product and uses them to promote a different, unrelated product ^[1]. And it prohibits company-controlled websites that claim to offer independent reviews when they are actually run by, or on behalf of, the business being reviewed ^[1].

The FTC filed this as a final Trade Regulation Rule under matter number R311003, following the standard federal rulemaking process ^[1]. The published notice runs to more than 900 kilobytes of Federal Register text, reflecting the detail behind the FTC's reasoning ^[1]. The source material provided does not include specific penalty amounts, enforcement actions taken so far, or the volume of public comments the FTC received before finalizing the rule. It is not yet known from these sources how aggressively the agency has pursued cases in the weight-loss drug space specifically.

Why it matters for patients

GLP-1 medications for weight loss and diabetes have generated a large online ecosystem of affiliate sites, comparison blogs, and social media accounts that review, rank, and recommend specific brands, telehealth services, and compounding pharmacies. Some of this content includes reviews or testimonials that readers may assume are independent and unpaid. The new FTC rule makes clear that fake reviews, undisclosed insider endorsements, and websites that look independent but are actually run by a seller are against federal law as of October 21, 2024 ^[1].

For a patient researching whether to try semaglutide or tirzepatide, or comparing a brand-name product to a compounded version, this matters because online reviews often shape those decisions. If a site's glowing testimonials about a product's effectiveness or a pharmacy's reliability turn out to be fabricated, secretly paid for, or written by people connected to the company, that content has misled the reader in a way the FTC now explicitly prohibits ^[1]. The rule does not evaluate any specific medication's safety or effectiveness. It addresses how reviews and testimonials about those products, and the businesses selling them, can be presented to consumers ^[1].

The rule also does not require review platforms to police every post themselves. Instead, it creates a basis for the FTC to act against businesses and individuals engaged in these deceptive practices ^[1]. Consumers reading GLP-1 content still need to evaluate sources critically, since a rule banning a practice is not the same as guaranteeing no company will violate it.

What happens next

The rule became enforceable on October 21, 2024 ^[1]. The sources provided do not include information about specific enforcement actions, complaints, or penalties issued under the rule since that date, so it is not yet known how the FTC has applied it in practice to GLP-1-related marketing or affiliate websites.